Niagen Bioscience (NAGE) Enterprise Value (2015 - 2026)
Niagen Bioscience (NAGE) posted quarterly Enterprise Value of -$66.5 million for Q1 2026, down 19.66% year-over-year from -$82.8 million in Q1 2025, and down 2.72% quarter-over-quarter from -$64.8 million in Q4 2025.
Niagen Bioscience (NAGE) Enterprise Value (2015 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Enterprise Value for 12 consecutive years, with -$66.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 19.66% year-over-year to -$66.5 million; the TTM figure through Mar 2026 stood at -$66.5 million (down 19.66% YoY), while the FY2025 annual figure was -$64.8 million, down 45.07% from the prior year.
- Enterprise Value declined to -$66.5 million in Q1 2026 per NAGE's latest filing, from -$64.8 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$13.3 million in Q3 2022 and bottomed at -$66.5 million in Q1 2026.
- Historically, Enterprise Value has averaged -$36.4 million across 5 years, with a median of -$27.6 million in 2024.
- Annual changes were most pronounced in 2022 — Enterprise Value jumped 59.94% — and 2025, when it plunged 116.87%.
- Niagen Bioscience's Enterprise Value stood at -$20.4 million in 2022, then sank by 33.68% to -$27.3 million in 2023, then tumbled by 63.44% to -$44.7 million in 2024, then sank by 45.07% to -$64.8 million in 2025, then declined by 2.72% to -$66.5 million in 2026.
- Business Quant data shows NAGE's Enterprise Value at -$66.5 million in Q1 2026, -$64.8 million in Q4 2025, and -$64.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | -66.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -66.74 Mn |
| Mar 31, 2026 | -66.55 Mn |
| Dec 31, 2025 | -64.79 Mn |
| Sep 30, 2025 | -64.29 Mn |
| Jun 30, 2025 | -60.47 Mn |
| Mar 31, 2025 | -55.62 Mn |
| Dec 31, 2024 | -44.66 Mn |
| Sep 30, 2024 | -32.40 Mn |
| Jun 30, 2024 | -27.89 Mn |
| Mar 31, 2024 | -27.57 Mn |
| Dec 31, 2023 | -27.33 Mn |
| Sep 30, 2023 | -26.77 Mn |
| Jun 30, 2023 | -26.41 Mn |
| Mar 31, 2023 | -23.14 Mn |
| Dec 31, 2022 | -20.44 Mn |
| Sep 30, 2022 | -13.26 Mn |
| Jun 30, 2022 | -17.07 Mn |
| Mar 31, 2022 | -20.99 Mn |
| Dec 31, 2021 | -28.22 Mn |
| Sep 30, 2021 | -33.10 Mn |